ADVERTISEMENT

Cipla Q3 Results Review - Strong Quarter; Key U.S. Launches Delayed: Prabhudas Lilladher

gAdvair and gAbraxane launches to be delayed by atleast two-three quarters.

<div class="paragraphs"><p>Photo by <a href="https://unsplash.com/@victoriabcphotographer?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash">Christina Victoria Craft</a> on <a href="https://unsplash.com/photos/orange-and-white-medication-pill-ZHys6xN7sUE?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash">Unsplash</a></p></div>
Photo by Christina Victoria Craft on Unsplash
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
You must be an existing Premium User
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit